top of page
The Professional Network for Healthcare Experts
Eli Lilly partners with Hims & Hers to expand access to Zepbound and Foundayo obesity medicines
Lilly's commercial partnership with Hims & Hers brings two FDA-approved obesity treatments into an integrated telehealth prescribing and delivery pathway, with published self-pay starting prices from $149 per month.
nuaxia
2 days ago2 min read
Zealand Pharma begins Phase 3 ZUPREME programme for petrelintide in obesity
Zealand Pharma and Roche have started the global Phase 3 ZUPREME programme evaluating once-weekly petrelintide as a treatment for people with overweight or obesity.
nuaxia
Sep 242 min read
bottom of page